名称 | EGFR Del19-T790M/BaF3 |
型号 | CBP73046 |
报价 | ![]() |
特点 | EGFR Del19-T790M/BaF3,母细胞:BaF3 |
产品搜索
相关文章
联系我们
电话:86-25-86880024
号码:86-25-86880024
手机:18066071954
地址:南京市雨花区长虹路222号
Email: zhangxiangwen@cobioer.com
产品展示 / PRODUCTS
药靶细胞株 > kinase激酶细胞株 > CBP73046EGFR Del19-T790M/BaF3

- 详细内容
CBP73046 | |
I. Introduction | |
Cell Line Name: | EGFR Del19-T790M/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10% FBS |
Mycoplasma Status: | Negative |
II.Background | |
EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section). In ligand-activated cancers, Cetuximab appears to be more effective than tyrosine-kinase inhibitors. | |
III. Representative Data | |
1.WB of EGFR Del19-T790M/BaF3 | |
2.Sanger of EGFR Del19-T790M/BaF3 | |
3. Anti-proliferation assay | |
Figure 4. Anti-proliferation assay of three reference compounds on the EGFR Del19-T790M/BaF3 Stable Cell Line. |